In short
Clinical trials investigating VARICELLA VIRUS OKA STRAIN (LIVE, ATTENUATED) are looking at revaccination in children and adolescents after childhood cancer treatment. These studies mainly assess immune response, especially antibody levels, and are focused on pediatric cancer populations.
Key points
- Clinical trials investigating VARICELLA VIRUS OKA STRAIN (LIVE, ATTENUATED) in the provided data focus on revaccination after childhood cancer treatment. The study includes children and adolescents from 0 to 18 years old with pediatric cancer. It is a Phase 3 interventional trial with 160 planned participants. The main goal is to measure immune response, especially IgG antibody levels for chickenpox and measles before and after vaccination. The trial is authorised and is studying whether revaccination leads to protective immunity.
Trial overview
This clinical study is a Phase 3 interventional trial that examines immunity after revaccination in children and adolescents treated for childhood cancer. The trial is authorised and plans to enroll 160 participants.
The study title says it examines cellular and humoral immunity against measles and chickenpox, meaning it looks at both immune cells and antibodies.
Who can participate
The target population is children and adolescents from 0 to 18 years of age with pediatric cancer. The trial is focused on people after treatment for childhood cancer, when doctors want to check whether vaccine protection is present again.
This means the study is not for the general population; it is designed for young patients who have already been treated for cancer.
What is being measured
The main endpoint is the difference in VZ IgG antibody levels before and after revaccination against chickenpox. IgG is a blood antibody that shows how the immune system responds to vaccination.
The study also measures the difference in measles IgG antibody levels before and after revaccination against measles. The brief summary states that the researchers want to compare the proportion of patients with a protective antibody level before and after vaccination.
These outcomes help show whether revaccination improves immune protection after cancer treatment.
Trial phase and design
This is an interventional study, which means the researchers give vaccines and then measure the results. It is listed as Phase 3, so it is studying the vaccine response in a larger group rather than only a small early group.
The interventions listed in the source include measles, mumps, and rubella live attenuated vaccine and varicella live attenuated vaccine, both given as 0.5 ml intramuscular injections. The trial data specifically focus on immune response after these revaccinations.
Study population and vaccines used
The study population includes young people recovering from childhood cancer treatment, a group that may need checks on whether prior vaccine protection is still present. The source also notes both cellular immunity and humoral immunity, which are two parts of the immune system that help defend against infection.
In simple terms, the researchers are asking whether these children and adolescents can build or regain measurable protection against chickenpox and measles after revaccination.
Why these trials matter
Children and adolescents treated for cancer can have changes in their immune response, so studies like this help check whether revaccination leads to protective antibody levels. The trial is important because it uses blood tests before and after vaccination to see if immunity improves.
By measuring antibody changes, the study can show whether revaccination against chickenpox and measles is working as expected in this patient group.